ABOUT US
Xiaobing Qian, MD, PhD
Chief Development Officer
Xiaobing Qian, MD, PhD, is Degron's Chief Development Officer. In this role, Dr. Qian leads the company's translational research, preclinical development and clinical development, as well as program management functions to advance the company's pipeline from development candidate nomination to clinical proof of concept.
Dr. Qian has more than 25 years of comprehensive novel drug discovery and development experience and proven tracker records in leading teams and projects in the US and China at several biotech companies. Dr. Qian has numerous patents and publications from her innovative work in RNA editing, gene therapy, small molecule kinase inhibitors, and biological drugs. She also contributed to various partnerships, licensing deals, acquisition, and funding successes.
Dr. Qian started her research career at Avigen, Inc, where she co-invented led preclinical testing of AAV gene therapy for the treatment of hemophilia A. She was Executive Director, Drug Development at CGI Pharmaceuticals, where she led target discovery and validation, pharmacology, and preclinical development of small molecule kinase inhibitor drugs for cancers and autoimmune diseases. Dr. Qian was Executive Director Early Clinical Development and Head Translational Medicine Strategy at Regeneron Pharmaceuticals, where she conducted indication research, led global clinical trials, and contributed to development strategy of blockbuster drugs across multiple therapeutic areas. Dr. Qian served as VP of Clinical Development and VP of Global Medical Evaluations & Strategy at Boston Pharmaceuticals, prior to joining Degron.
Dr. Qian received her MD from Peking University Medical School and holds USMLE certificate. She obtained her PhD in Biochemistry and Molecular Biology from the University of Illinois College of Medicine, Chicago. Her postdoctoral research at the Gladstone Institutes at the University of California, San Francisco was supported by American Heart Association Grants. Dr. Qian completed her study of TRIUM Global EMBA, a premier program delivered by NYU Stern/London School of Economics/Paris HEC.
Xiaobing Qian, MD, PhD
Chief Development Officer
Xiaobing Qian, MD, PhD, is Degron's Chief Development Officer. In this role, Dr. Qian leads the company's translational research, preclinical development and clinical development, as well as program management functions to advance the company's pipeline from development candidate nomination to clinical proof of concept.
Dr. Qian has more than 25 years of comprehensive novel drug discovery and development experience and proven tracker records in leading teams and projects in the US and China at several biotech companies. Dr. Qian has numerous patents and publications from her innovative work in RNA editing, gene therapy, small molecule kinase inhibitors, and biological drugs. She also contributed to various partnerships, licensing deals, acquisition, and funding successes.
Dr. Qian started her research career at Avigen, Inc, where she co-invented led preclinical testing of AAV gene therapy for the treatment of hemophilia A. She was Executive Director, Drug Development at CGI Pharmaceuticals, where she led target discovery and validation, pharmacology, and preclinical development of small molecule kinase inhibitor drugs for cancers and autoimmune diseases. Dr. Qian was Executive Director Early Clinical Development and Head Translational Medicine Strategy at Regeneron Pharmaceuticals, where she conducted indication research, led global clinical trials, and contributed to development strategy of blockbuster drugs across multiple therapeutic areas. Dr. Qian served as VP of Clinical Development and VP of Global Medical Evaluations & Strategy at Boston Pharmaceuticals, prior to joining Degron.
Dr. Qian received her MD from Peking University Medical School and holds USMLE certificate. She obtained her PhD in Biochemistry and Molecular Biology from the University of Illinois College of Medicine, Chicago. Her postdoctoral research at the Gladstone Institutes at the University of California, San Francisco was supported by American Heart Association Grants. Dr. Qian completed her study of TRIUM Global EMBA, a premier program delivered by NYU Stern/London School of Economics/Paris HEC.
